Mutations in this gene can cause abnormal activation of this pathway, leading to uncontrolled cellular proliferation that could cause AML cells to develop resistance to crenolanib, a FLT3 inhibitor [58]. This evidence concerns the gene FLT3 and acute myeloid leukemia.